Skip to content
Medical-conditions — Stay on Top of Your Wellness — Monitor Your Financial Health — Headline: Boost Your Business Productivity

Ultragenyx Appoints Eric Olson as New CBO to Drive Rare Disease Therapies

Eric Olson, a seasoned biopharma veteran, joins Ultragenyx to lead business development. His expertise in strategic partnering will help expand access to rare disease treatments.

,   and  Administrator
1 min read
This image is clicked in a room, where it looks like Store. There are so many bottles in this image...
This image is clicked in a room, where it looks like Store. There are so many bottles in this image and cans. There is a Banner in the middle which is indicating Supra brand. Bottom right corner there is a logo LM.

Ultragenyx Appoints Eric Olson as New CBO to Drive Rare Disease Therapies

Ultragenyx Pharmaceuticals has appointed Eric Olson as its new chief business officer (CBO) and executive vice president, effective September 22, 2025. Olson brings nearly two decades of experience in the biopharma industry, with a strong focus on business development and strategic partnering, particularly in rare diseases.

Olson joins Ultragenyx from Stoke Therapeutics, where he served as CBO. In this role, he led the company's landmark partnership with Biogen for zorevunersen outside North America. Prior to Stoke, Olson held various leadership positions in business development at Alnylam Pharmaceuticals and Takeda. At Alnylam, he was vice president and head of business development, overseeing the $2.8 billion collaboration between Alnylam and Roche. At Takeda, he was vice president and head of Rare Disease and Immunology Global Business Development.

Olson has represented several prominent biopharma companies throughout his career, including Stoke Therapeutics, Alnylam Pharmaceuticals, Takeda, and Genzyme Corporation. He has played a pivotal role in numerous significant collaborations, such as Stoke's partnership with Biogen.

Olson's appointment comes as Ultragenyx thanks outgoing CBO Thomas Kassberg for his 14 years of service. Kassberg played a crucial role in building Ultragenyx's rare disease pipeline and expanding patient reach. Olson will now lead Ultragenyx's business development, corporate development, and alliance management functions, aligning with the company's commitment to bringing novel therapies to patients with serious rare and ultra-rare genetic diseases.

Read also:

Related

Latest